Document Detail

Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis.
MedLine Citation:
PMID:  19797187     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: High blood pressure (BP) is common in acute ischemic stroke and associated independently with a poor functional outcome. However, the management of BP acutely remains unclear because no large trials have been completed.
METHODS: The factorial PRoFESS secondary stroke prevention trial assessed BP-lowering and antiplatelet strategies in 20 332 patients; 1360 were enrolled within 72 hours of ischemic stroke, with telmisartan (angiotensin receptor antagonist, 80 mg/d, n=647) vs placebo (n=713). For this nonprespecified subgroup analysis, the primary outcome was functional outcome at 30 days; secondary outcomes included death, recurrence, and hemodynamic measures at up to 90 days. Analyses were adjusted for baseline prognostic variables and antiplatelet assignment.
RESULTS: Patients were representative of the whole trial (age 67 years, male 65%, baseline BP 147/84 mm Hg, small artery disease 60%, NIHSS 3) and baseline variables were similar between treatment groups. The mean time from stroke to recruitment was 58 hours. Combined death or dependency (modified Rankin scale: OR, 1.03; 95% CI, 0.84-1.26; P=0.81; death: OR, 1.05; 95% CI, 0.27-4.04; and stroke recurrence: OR, 1.40; 95% CI, 0.68-2.89; P=0.36) did not differ between the treatment groups. In comparison with placebo, telmisartan lowered BP (141/82 vs 135/78 mm Hg, difference 6 to 7 mm Hg and 2 to 4 mm Hg; P<0.001), pulse pressure (3 to 4 mm Hg; P<0.002), and rate-pressure product (466 mm Hg.bpm; P=0.0004).
CONCLUSIONS: Treatment with telmisartan in 1360 patients with acute mild ischemic stroke and mildly elevated BP appeared to be safe with no excess in adverse events, was not associated with a significant effect on functional dependency, death, or recurrence, and modestly lowered BP.
Philip M W Bath; Reneé H Martin; Yuko Palesch; Daniel Cotton; Salim Yusuf; Ralph Sacco; Hans-Christoph Diener; Danilo Toni; Conrado Estol; Robin Roberts;
Related Documents :
16904557 - Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progress...
10723117 - Blood pressure control in subjects with type 2 diabetes.
7917147 - Hostility and the response to diuretic in mild-to-moderate hypertension.
24694797 - High rates of non-adherence to antihypertensive treatment revealed by high-performance ...
16217067 - L-dops therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy.
3643887 - Successful treatment of experimental neonatal respiratory failure using extracorporeal ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-09-24
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  40     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-27     Completed Date:  2009-11-23     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3541-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Blood Pressure / drug effects,  physiology
Brain Ischemia / drug therapy*,  physiopathology,  prevention & control
Follow-Up Studies
Hypertension / drug therapy*,  physiopathology,  prevention & control
Middle Aged
Recurrence / prevention & control
Stroke / drug therapy*,  physiopathology,  prevention & control
Reg. No./Substance:
0/Benzimidazoles; 0/Benzoates; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differences in the evolution of the ischemic penumbra in stroke-prone spontaneously hypertensive and...
Next Document:  Interrater Agreement for Final Infarct MRI Lesion Delineation.